<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04489836</url>
  </required_header>
  <id_info>
    <org_study_id>Project 0470-Pilot study</org_study_id>
    <nct_id>NCT04489836</nct_id>
  </id_info>
  <brief_title>GlutDigest - Pilot Study</brief_title>
  <acronym>GlutDigestP</acronym>
  <official_title>GlutDigest - Enzymes-assisted Gluten Digestion (Pilot Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deerland Enzymes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teagasc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Atlantia Food Clinical Trials</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Deerland Enzymes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot, feasibility study to evaluate, test and optimize sample analysis procedures&#xD;
      and protocols before the full-scale, crossover study is conducted.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two important factors can influence the proportions of gluten and starch that resist&#xD;
      digestion: (1) enzyme availability and specificity and (2) the structural properties of the&#xD;
      food. A complete evaluation of gluten digestion and of the impact of dietary supplements is&#xD;
      difficult to conduct because it is not easy to obtain samples of digestive chime. The&#xD;
      analysis of the ileal effluent of healthy ileostomy patients constitutes a non-invasive&#xD;
      alternative to intubation techniques for the study of nutrient digestion and of the fate of&#xD;
      probiotics in the small intestine.&#xD;
&#xD;
      The main aim of this study is to test and optimize sample analysis protocols before&#xD;
      conducting the full-scale, crossover study which will aim at evaluating the impact of two&#xD;
      dietary supplements (Glutalytic® and DE111®) and of oatmeal properties on the digestion of&#xD;
      gluten and starch and on the glycemic response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 31, 2020</start_date>
  <completion_date type="Actual">September 19, 2020</completion_date>
  <primary_completion_date type="Actual">September 19, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Undigested wheat protein after each treatment</measure>
    <time_frame>9-hour period after the test meal</time_frame>
    <description>Difference between the mean concentration of undigested wheat protein in ileal effluent samples.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vegetative DE111 cells</measure>
    <time_frame>9-hour period after the test meal</time_frame>
    <description>Mean concentration of DE111® cells recovered in the ileal effluent samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic response</measure>
    <time_frame>At baseline, and at different time-points in the 9-hour period after consumption of the test meal.</time_frame>
    <description>Difference between the mean area under the glucose concentration (measured in the interstitial fluid) curves following each treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Undigested starch</measure>
    <time_frame>9-hour period after the test meal</time_frame>
    <description>Difference between the mean concentration of undigested starch in ileal effluent samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Undigested food particles</measure>
    <time_frame>9-hour period after the test meal</time_frame>
    <description>Pictures of undigested foods particles and microscopy will be combined for a combined assessment of macro- and micro- structural characteristics of the food particles recovered in ileal effluent samples.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Main Focus: Gluten and Starch Digestibility</condition>
  <arm_group>
    <arm_group_label>Meal A + Glutalytic®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>350 mg Glutalytic® capsule, taken by mouth, once, with Meal A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meal A + DE111®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>350 mg DE111® capsule, taken by mouth, once, with Meal A</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glutalytic®</intervention_name>
    <description>Glutalytic® capsule</description>
    <arm_group_label>Meal A + Glutalytic®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>DE111®</intervention_name>
    <description>DE111® capsule</description>
    <arm_group_label>Meal A + DE111®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Meal A</intervention_name>
    <description>Oatmeal porridge - serving of oat porridge (cooked) containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL</description>
    <arm_group_label>Meal A + DE111®</arm_group_label>
    <arm_group_label>Meal A + Glutalytic®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has given written informed consent&#xD;
&#xD;
          -  Subject has an ileostomy stable for at least 3 months post-operative and shows normal&#xD;
             stoma functions&#xD;
&#xD;
          -  Subject is otherwise healthy&#xD;
&#xD;
          -  Subject is available to participate in the study sessions on the proposed dates&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has coeliac disease or allergy to wheat products and/or any other ingredients&#xD;
             in the test meal and standard meals&#xD;
&#xD;
          -  Case of obstruction of the stoma in the past 3 months&#xD;
&#xD;
          -  Body mass index &lt; 18 kg/m2 or &gt; 30 kg/m2.&#xD;
&#xD;
          -  Diagnosed mouth, throat or active gastrointestinal pathology (other than ileostomy)&#xD;
             that may affect normal ingestion and digestion of food.&#xD;
&#xD;
          -  History of pancreatic disease&#xD;
&#xD;
          -  Subject is immunocompromised (HIV positive, transplant patient, on antirejection&#xD;
             medications, on a steroid for &gt;30 days, or chemotherapy or radiotherapy within the&#xD;
             last year)&#xD;
&#xD;
          -  Subject has Type 1 or Type 2 diabetes mellitus.&#xD;
&#xD;
          -  Subject has a history of bariatric surgery.&#xD;
&#xD;
          -  Subject has a history of drug and/or alcohol abuse at the time of enrolment&#xD;
&#xD;
          -  Subject is currently participating in another study, or plans to participate in&#xD;
             another study during the study period&#xD;
&#xD;
          -  Women of child-bearing potential who do not use an acceptable method of contraception&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Atlantia Food Clinical Trials</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2020</study_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gluten</keyword>
  <keyword>Starch</keyword>
  <keyword>Digestive enzymes</keyword>
  <keyword>Probiotics</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

